MCC  'Tardy' as couple suffer Mefliam 'nightmare’ by Bateman, Chris
IZINDABA
429
June 2009, Vol. 99, No. 6  SAMJ
The Medicines Control Council (MCC) took 20 months to 
respond to an urgent Cipla-Medpro application to include 
vital new safety information 
in their generic antimalarial 
tablet Mefliam packaging, 
forcing the drug company to 
go ahead regardless.
Now a middle-aged 
KwaZulu-Natal couple 
are suing Cipla for over 
R1 million after allegedly 
suffering years of anxiety, 
insomnia, depression and 
income loss – which they 
claim is a result of taking 
Mefliam with inadequate 
package warnings. 
The aggrieved couple also 
laid criminal complaints 
accusing Cipla of trading 
without a valid drug 
registration certificate and 
failing to include appropriate 
and timely health packaging 
warnings. At the time of 
writing the Commercial 
Crimes Unit was probing 
this.
However, Superintendent 
Kallie Lourens, of the 
Commercial Crimes Unit 
in Cape Town (where the 
Cipla Medpro headquarters 
are), said his men would be 
visiting the MCC in Pretoria 
to verify Cipla’s claims that 
it registered Mefliam ‘by the 
book’. ‘It also seems there 
are no statutory provisions 
requiring all the relevant 
drug package information 
on the generic drug to match 
that of the original (ethical) 
drug but we’ll double-check 
this at the MCC,’ he added.
MCC Registrar, Ms 
Mandisa Hela told Izindaba 
(after conducting her own 
probe) that she was ‘satisfied there were no irregularities with 
the registration’. However, it emerged from documentation that 
the MCC took 20 months to respond to the Cipla application 
to amend their Mefliam package insert to reflect additional 
information. This included psychiatric disorders under the 
headings ‘contraindications, warnings, side-effects and special 
precautions’.
Cipla Medpro said their request for a new package insert 
was made in October 2002, after the company was alerted to a 
Medinfo press release entitled ‘Suicide alert issued on malaria 
drug’. This press release prompted Cipla to consult the Federal 
Drug Administration (FDA) website that contained an updated 
mefloquine package insert.
The MCC evaluated Cipla’s request and responded in June 
2004, asking that the package insert be ‘brought into line with 
the innovator product Lariam (Roche)’
It also asked Cipla to respond to this recommendation 
‘within six months’ and when Cipla failed to do so, sent a 
reminder on 23 October  last year. ‘We’re still checking to 
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see whether there was a 
response or not,’ Hela told 
Izindaba on 29 April this 
year.
Dr Nic de Jongh, 
Medical Director of Cipla 
Medpro, said the original 
MCC request to amend 
was ‘done in the public 
interest’ by way of sending 
the MCC a newly drafted 
package insert. In spite of 
the ensuing nearly 2-year 
delay (the MCC eventually sent them back the wrong insert) 
his company had gone ahead and included the new packaging 
information in all Mefliam boxes from December 2002. ‘Due to 
the severity of the warnings, we had no doubt at the time that 
it was our responsibility to warn patients of these potentially 
serious adverse effects,’ he wrote in a January 2009 letter to the 
MCC.
Hela earlier told Izindaba that medicines were registered 
on the basis of clinical trials with contraindications signals 
sometimes only picked up once the drugs were in the field. 
The packaging was then updated accordingly. ‘Every medicine 
registered or information required is a living document. Safety 
information changes dynamically and we ask the applicant to 
adapt accordingly.’
She did not explain why it took the MCC so long to process 
Cipla’s request. De Jongh said the drug’s actual registration 
was a ‘matter of public record in the government gazette’, 
adding that it was ‘up to the court to decide’ on the legitimacy 
of the civil claim. ‘Our version of the facts is quite simple. 
There was an FDA warning about suicide risk which we 
updated (on the package insert) with any new side-effects 
about the time the complainants came with their insomnia 
claims. Their symptoms were included in the update when we 
got the FDA alert’ he said.
In the claim before the High Court in Durban, insurance 
broker Paul Kotze (48) and his wife Sharon (47), of Kloof, said 
they took Mefliam before, during and after a Mozambique 
holiday in June and July of 2002.
Soon after arriving at their destination, Marangula Cottages, 
they and their two sons, Kelvin (then 13) and Christopher 
(11) began suffering from insomnia. After a ‘nightmare’ trip 
back home their GP’s locum advised them to complete the 
Mefliam course but added sleeping tablets and some vitamin 
B injections to address the symptoms. A fortnight later their 
own GP put Sharon, who was by then suffering ‘insomnia-
related anxiety attacks, intense fatigue and headaches’, onto 
Doxyhexal, another antimalarial.
Her husband also suffered from insomnia, high temperatures 
and headaches, even though malaria and other probable causes 
were eliminated. After 2 months of sleeping tablets having 
‘little effect’, Paul Kotze had lost weight while Sharon began 
suffering blurred vision, slurred speech and suicidal ideation 
by October that year (as a result of sleep deprivation), and 
was put on antidepressants. The couple, who said they ran 
marathons, swam competitively and lived a highly sociable life 
before the holiday, began to withdraw socially. They described 
themselves to concerned friends as ‘zombies’.
Lives turned upside down
The Kotzes described themselves as financially independent 
with no abnormal stresses or pressures before their ordeal 
began, neither having ever suffered from any form of 
depression, sleeping well to awake around 4am daily when 
they would usually go for a run or cycle.
By January 2003 Sharon had resigned from her three 
mornings a week half-day job and was suffering from ‘chronic 
sleep deprivation, forgetfulness, impaired vision, pins and 
needles around her head and down the back of her shoulders 
and ongoing slurred speech plus loss of libido’. Her husband 
continued to suffer ‘ringing ears, blurred vision, short-term 
memory loss, loss of libido, chronic fatigue, depression and 
anxiety’, all symptoms she shared.
Sharon then got in touch with de Jongh, who promised input 
from other specialists, saying he would get back to them. This 
gave them ‘short-lived hope, but no solution’.
They said a specialist physician and a psychiatrist were 
unsure of how to treat/solve their conditions, outside of 
continuing to take sleeping tablets and antidepressants. 
The Kotzes complained to the company about the lack of 
‘appropriate’ warnings on the Mefliam package insert, 
contending that insomnia and other side-effects should have 
been included. 
De Jongh told Izindaba that he had tried to help Sharon 
when she contacted him when she was struggling with her 
dependence on sleeping tablets, but later they claimed that 
the only reason that he helped them was because of their 
impending court action. He 
said that ‘this is a crusade’ 
and that the Kotzes would 
explore every possible 
avenue to gain leverage.
According to 
court documents, 
Sharon underwent a 
polysomnogram in July 2005 
which confirmed extremely 
low levels of sleep. Her 
husband allegedly only 
began sleeping lightly after 
3.5 years. 
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The Kotzes claim there were no warnings about suicidal 
ideation, sleep disorders, insomnia and the potential dangers 
to pregnant women on the package insert at the time, but that 
these were hastily added in December 2002. They discovered 
months later that the package insert for Lariam (the ethical 
equivalent and dated 17 January 1997) included warnings 
of insomnia and sleep disorders as well as flagging ‘toxic 
encephalopathy of unknown etiology during prophylaxis’. 
Lariam warned users that the most frequently reported side-
effects were nausea and sleep disorders (insomnia, abnormal 
dreams). Mefliam, however, in their original package insert 
(August 1997), allegedly had no such warnings.
In their ‘particulars of claim’, the Kotzes also say the 
company failed to take ‘any or adequate steps’ to warn users 
that once they experienced such adverse effects, they should 
desist from continuing to use the tablets.
In their initial filing of court papers, Paul Kotze claims to 
have lost R420 000 and his wife R378 000 in income over 3.5 
years, R5 040 000 and R42 000 in medical and/or hospital 
expenses respectively, and R180 000 and R240 000 respectively 
in diminution of the enjoyment of the amenities of life, 
including the listed adverse effects.
•    Lariam was developed by the United States military during the 
Vietnam War when ground troops displayed resistance to the 
standard chloroquine then in use. Side-effects listed on its label 
include adverse heart, kidney, liver, skin, central and peripheral 
nervous system and psychiatric problems. 
•    In 2003, the British Medical Journal published research by 
Swiss scientists comparing Lariam to three other antimalarial 
drugs. They found that 41.6% of the patients taking Lariam 
experienced moderate to severe neuropsychiatric side-effects, 
almost twice as many as those taking doxycycline or Malarone.
•    In a rare move in July 2003, the United States Food and Drug 
Administration (FDA) ordered that patients be warned directly 
of serious mental problems and reports of suicide linked to 
Lariam, ordering doctors to hand patients a ‘medication guide’ 
with the new Lariam warnings.
•    A mefloquine neurotoxicity literature review1  reveals that 
mefloquine neurotoxicity has been demonstrated at both the 
preclinical and clinical levels, with nausea, dizziness, sleep 
disturbances, anxiety and psychosis, among other adverse 
neuropsychiatric events reported in users. Females and 
individuals of low body mass index are at apparent greater risk.
•    The Kotze civil claim is set down for 27 July in the Durban High 
Court.
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